Question 1

What is LL-37?

Accepted Answer

LL-37 is a 37-amino acid antimicrobial peptide and the only human cathelicidin. It is a key component of the innate immune system, produced by immune cells, epithelial cells, and other tissues in response to infection or injury. LL-37 was first identified from human neutrophils and is encoded by the CAMP gene.

Question 2

What are the research benefits of LL-37?

Accepted Answer

Research on LL-37 has investigated its potential effects in several areas, including: Broad-spectrum antimicrobial (bacteria, fungi, viruses); Anti-biofilm activity (disrupts bacterial biofilms); Studied for wound healing and tissue repair; Immunomodulatory — balances immune response. These findings are primarily from preclinical and animal studies unless otherwise noted. Results may not translate directly to humans.

Question 3

How does LL-37 work?

Accepted Answer

LL-37 disrupts microbial membranes through electrostatic interaction with negatively charged pathogen surfaces, creating pores that kill bacteria, fungi, and enveloped viruses. As an immunomodulator, it activates formyl peptide receptor 2 (FPR2), promoting chemotaxis of immune cells, angiogenesis, and wound healing. It also neutralizes bacterial lipopolysaccharide (LPS), reducing endotoxin-driven inflammation.

Question 4

What is the FDA/legal status of LL-37?

Accepted Answer

LL-37 is not currently FDA-approved for human therapeutic use. It is classified as a research compound and is available for research use only. It has not been evaluated for safety or efficacy in humans by regulatory agencies. Always consult applicable laws in your jurisdiction before purchase or use.

Question 5

What are the known risks or side effects of LL-37?

Accepted Answer

Based on available research, LL-37 has been associated with the following in study settings: Injection site reactions; Potential for mast cell activation at high concentrations; Limited human dosing data for exogenous administration; May cause histamine-related effects. Long-term safety data in humans is limited or absent for most research peptides. This should not be taken as a complete safety profile.

Question 6

Where can I find published research on LL-37?

Accepted Answer

Published research on LL-37 can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for "LL-37" or its aliases (Cathelicidin, hCAP-18) to find peer-reviewed studies. PEP.WIKI aggregates key studies with abstracts and study type classifications on each compound's research page.

LL-37

Overview

Mechanism of Action

Key Research Benefits

Clinical Evidence Summary

Key Studies / PubMed References

LL-37, the master antimicrobial peptide, its multifaceted role from combating infections to cancer immunity.

Human antimicrobial/host defense peptide LL-37 may prevent the spread of a local infection through multiple mechanisms: an update.

Cathelicidin LL-37 in periodontitis: current research advances and future prospects - A review.

Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications.

Exploring the Antimicrobial Potential of LL-37 Derivatives: Recent Developments and Challenges.

Side Effects & Safety

Known Interactions

Frequently Asked Questions

Research Disclaimer